|
|
|
|
|
CUSIP No. 81577F109
|
|
Schedule 13G
|
|
Page 2 of 4
|
This Amendment No. 2 amends the Reporting Persons statement on Schedule 13G filed on April 15, 2019 with
respect to the Common Stock of the Issuer.
ITEM 1.(a)
|
Name of Issuer:
|
Seelos Therapeutics, Inc. (the Issuer).
(b) Address of Issuers Principal Executive Offices:
300 Park Avenue, 12th Floor, New York, NY 10022.
ITEM 2.(a)
|
Name of Person Filing:
|
This statement is filed on behalf of Ligand Pharmaceuticals Incorporated (the Reporting Person).
(b) Address or Principal Business Office:
The business address of the Reporting Person is 3911 Sorrento Valley Boulevard, Suite 110, San Diego CA 92121.
(c) Citizenship of each Reporting Person is:
The Reporting Person is organized in the State of Delaware.
(d) Title of Class of Securities:
Common Stock, par value $0.001 per share (the Common Stock).
(e) CUSIP Number:
81577F109
Not applicable.
The ownership information below represents beneficial ownership of Common Stock of the Issuer as of December 31, 2020, based upon
54,535,891 shares of Common Stock outstanding as of December 31, 2020, and assumes the full exercise of warrants (exercisable as of December 31, 2020 for the purchase 302,419 shares of Common Stock of the Issuer) held by the Reporting
Person. The 54,535,891-shares figure was provided to the Reporting Person by the Issuer, upon inquiry.
(a) Amount beneficially owned:
The Reporting Person is the record holder of 1,921,581 shares of Common Stock and warrants to purchase 302,419 shares of Common Stock that are
currently exercisable. Pursuant to the terms of the warrants, the Reporting Person may not exercise the warrants (or a portion thereof) if, as a result of such exercise, the Reporting Person would beneficially own in excess of 9.99% of the shares of
Common Stock outstanding immediately following the exercise. The blocker position is not currently implicated, due to the Reporting Persons current beneficial ownership percentage.